News
- Author:
- Michele G. Sullivan
Publish date: January 9, 2018
Of 3,990 patients with mRCC, 79% received an appropriate first-line treatment, but only 20% went on to get a second-line agent.
News
- Author:
- Michele G. Sullivan
Publish date: January 9, 2018
Simultaneously, Axovant Life Sciences pulls plug on intepirdine, another 5-HT6 receptor drug, after failures in both AD and Lewy body dementia.
News
- Author:
- Michele G. Sullivan
Publish date: January 5, 2018
American CryoStem markets the product mainly for neurologic indications.
News
- Author:
- Michele G. Sullivan
Publish date: December 26, 2017
BOSTON – Temporal lobe tau accumulation in cognitively normal older adults may be a good way of tracking Alzheimer’s disease progression.
News
- Author:
- Michele G. Sullivan
Publish date: December 26, 2017
The effects of an unguarded social media post can be profound and long-lasting for surgeons.
News
- Author:
- Michele G. Sullivan
Publish date: December 19, 2017
The findings reinforce the FDA’s warnings that these devices shouldn’t be used to remove fibroids from some women.
News
- Author:
- Michele G. Sullivan
Publish date: December 18, 2017
The ADA document is the first to support use of these drugs for their cardioprotective effect.
News
- Author:
- Michele G. Sullivan
Publish date: December 13, 2017
A primary prevention treatment that cut the risk of amyloidosis would sharply decrease this number, the modeling study found.
News
- Author:
- Michele G. Sullivan
Publish date: December 12, 2017
BERLIN – Teens who report psychotic experiences at baseline are at a much higher risk of developing persistent psychosocial problems that may devel...
News
- Author:
- Michele G. Sullivan
Publish date: December 12, 2017
Whether reducing the mutant huntingtin protein with the antisense oligonucleotide IONIS-HTTRx helps patients remains to be seen.
News
- Author:
- Michele G. Sullivan
Publish date: December 11, 2017
Following a low-calorie diet for 1 year is enough to reverse type 2 diabetes.
News
- Author:
- Michele G. Sullivan
Publish date: December 11, 2017
Now a larger efficacy trial is warranted, the investigators said.
News
- Author:
- Michele G. Sullivan
Publish date: December 8, 2017
SAN DIEGO – The Z1071 landmark study proves the safety of leaving the axilla intact in node-positive patients who respond well to neoadjuvant chemo...
News
- Author:
- Michele G. Sullivan
Publish date: December 7, 2017
Many patients couldn’t get back into remission when adalimumab was reinstated.
News
- Author:
- Michele G. Sullivan
Publish date: December 4, 2017
BOSTON – The retina could be “a window that could let us see what’s happening in the brain in early Alzheimer’s disease.”
